NCT00486005已完成4 期
Weight Gain Management in Patients With Schizophrenia During Treatment With Olanzapine in Association With Nizatidine
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 74
- 试验地点
- 1
- 主要终点
- Evaluate the effect of olanzapine associated to nizatidine compared to olanzapine associated to placebo to prevent/control weight gain
研究概览
简要总结
Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with schizophrenia who have been under treatment with olanzapine for at least two months and evaluate the treatment effects on the Eating Inventory, BPRS, number of treatment, emergent adverse events, changes in vital signs, laboratory results and extrapyramidal effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients, men or women, with age of 18 to 65 years
- •Patients must have schizophrenia that meets disease diagnostic criteria as defined in DSM-IV Sections 295.10, 295.20, 295.30, or 295.90 and not to be in a clinically acute phase, in accordance with the judgment of the investigator
- •Patients in use of 5 mg/day and 20 mg/day of olanzapine for a period not less than 2 months and not greater than 6 months and that have increased at least 5% of their corporal weight since the beginning of the treatment with olanzapine.
- •The individuals must be trustworthy, and have a level of understanding enough to carry out all the tests and examinations demanded for the protocol, to understand the nature of the study and to have signed the informed consent
- •Women with potential to become pregnant must be using a medically acceptable and reliable means of birth control.
排除标准
- •Participation in a clinical study of another drug in investigation within a period of 1 month (30 days) before the entrance in the study (Visit 1)
- •People who have used clozapine within a period of 12 months before the beginning of the study
- •People with diagnosis of diabetes mellitus types I or II without adjusted clinical control or have initiated the medication use for glycemic control in the last 6 months
- •DSM-IV substance (except nicotine and caffeine) dependence within the past 30 days
- •Current participation in programs of weight loss
结局指标
主要结局
Evaluate the effect of olanzapine associated to nizatidine compared to olanzapine associated to placebo to prevent/control weight gain
次要结局
- Compare the effect of olanzapine with nizatidine or placebo evaluated by the average alteration between the groups in cognitive control of appetite, disinhibition and susceptibility to hunger, variation of weight and total punctuation in BPRS
- Compare the security of the association of olanzapine with nizatidine and olanzapine and placebo in relation to laboratory values, vital signs, and incidence of extrapyramidal symptoms
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic SubjectsSchizophreniform DisorderSchizophreniaSchizoaffective DisorderNCT00734435Orexigen Therapeutics, Inc26
已完成
4 期
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational ProgrammeWeight GainNCT00191828Eli Lilly and Company60
终止
不适用
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for SchizophreniaMetabolic SyndromeNCT00794963Northwell Health8
已完成
不适用
Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental IllnessSchizophreniaBipolar DisorderSchizoaffective DisorderNCT00661869Manhattan Psychiatric Center295
已完成
不适用
Bariatric Surgery in Patients With SchizophreniaObesitySchizophreniaNCT06043206Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau100